Submissions for variant NM_170606.3(KMT2C):c.3462del (p.Leu1155_Val1156insTer)

dbSNP: rs1588343792

Total submissions: 1

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine	RCV000826194	SCV000967744	pathogenic	Kleefstra syndrome due to a point mutation	2018-10-12	criteria provided, single submitter	clinical testing	The p.Val1156X variant in KMT2C has not been previously reported in diseased ind ividuals, nor in large population studies. However, this variant was confirmed t o be de novo in an individual with mild intellectual disability, autism, seizure s, sensorineural hearing loss, gastroparesis, and supraventricular tachycardia b y the Broad Institute Rare Genomes Project. This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at positio n 1156 and leads to a premature termination codon at this position. This alterat ion is then predicted to lead to absent protein. Heterozygous loss of function o f the KMT2C gene is an established disease mechanism in individuals with Kleefst ra 2 syndrome. In summary, this variant meets criteria to be classified as patho genic for Kleefstra 2 syndrome in an autosomal dominant manner based upon de nov o occurrence, its absence from the general population, and its predicted impact on the protein. ACMG/AMP Criteria applied: PVS1, PS2, PM2.